OncoMatch

OncoMatch/Clinical Trials/NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Is NCT06586515 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for pancreatic ductal adenocarcinoma.

Phase 1RecruitingEli Lilly and CompanyNCT06586515Data as of May 2026

Treatment: LY3962673 · Cetuximab · Gemcitabine · nab-paclitaxel · Oxaliplatin · leucovorin · Irinotecan · 5-fluorouracil — The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Non-Small Cell Lung Carcinoma

Colorectal Cancer

Biomarker criteria

Required: KRAS g12d mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic chemotherapy — advanced or metastatic disease

Lab requirements

Cardiac function

No significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction

significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California
  • University of California, Los Angeles (UCLA) · Los Angeles, California
  • Sarah Cannon Research Institute at HealthOne · Denver, Colorado
  • Sibley Memorial Hospital · Washington D.C., District of Columbia
  • Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute · Orlando, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify